Skip to main content
Erschienen in: Current Diabetes Reports 2/2019

01.02.2019 | Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)

Economic Impact of Diabetes in Africa

verfasst von: Clarisse Mapa-Tassou, Jean-Claude Katte, Camille Mba Maadjhou, Jean Claude Mbanya

Erschienen in: Current Diabetes Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review seeks to address knowledge gaps around the economic burden of diabetes in Africa. Africa is home to numerous endemic infections and also prevalent non-communicable diseases including diabetes. It is projected that the greatest increases in diabetes prevalence will occur in Africa. The importance of this review therefore lies in providing adequate knowledge on the economic challenges that diabetes poses to the continent and describe the way forward in tackling this epidemic.

Recent Findings

Diabetes contributes to a huge amount of the global health expenditure in the world. There is a dearth of information on the economic burden of diabetes in Africa with very limited number of studies in the area. Predictions do show that Africa has the greatest predicted increase in both the burden of diabetes and associated diabetic complications but yet contributes the lowest in the global annual healthcare expenses with regard to diabetes care. In 2017, the International Diabetes Federation (IDF) estimated the total health expenditure due to diabetes at $3.3 billion. In Nigeria, the national annual direct costs of diabetes was estimated in the range of $1.071 billion to $1.639 billion per year while the estimated monthly direct medical costs per individual in Cameroon stands at $148. In Sudan, the direct cost of type 2 diabetes control was $175 per year which only included the cost of medications and ambulatory care. People with diabetes are likely to experience one or more chronic illness and a significant portion of the costs associated with these complications are attributed to the underlying diabetes.

Summary

The growing epidemics of diabetes and associated diabetic complications worldwide poses catastrophic financial costs, especially in Africa where most of the expenses are paid by patients and families. The most common method used for the estimation of the economic burden of a public health problem like diabetes is the cost-of-illness approach. Cost-of-illness studies traditionally divide costs into three categories: direct, indirect, and intangible. The IDF estimated the total health expenditure due to diabetes at $3.3 billion worldwide in 2017. Most of the existing studies in Africa estimated only the direct costs. The medical direct cost of type 1 diabetes was higher than type 2. However, the estimations of costs of diabetes in many countries in Africa may be underestimated due to absence of data on the relative contribution of cost of diabetes complications.
Literatur
1.
Zurück zum Zitat Atun R, Gale EAM. The challenge of diabetes in sub-Saharan Africa. Lancet Diabetes Endocrinol. 2015;3:675–7.CrossRef Atun R, Gale EAM. The challenge of diabetes in sub-Saharan Africa. Lancet Diabetes Endocrinol. 2015;3:675–7.CrossRef
2.
Zurück zum Zitat • Atun R, Davies JI, Gale EAM, Bärnighausen T, Beran D, Kengne AP, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol. 2017;5:622–67 This article provides an up-to-date situational analysis with regards to the diabetes challenges and perspectives for transforming the diabetes landscape in the continent. It further identifies current gaps in economic policies which may serve as landmarks for action.CrossRef • Atun R, Davies JI, Gale EAM, Bärnighausen T, Beran D, Kengne AP, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol. 2017;5:622–67 This article provides an up-to-date situational analysis with regards to the diabetes challenges and perspectives for transforming the diabetes landscape in the continent. It further identifies current gaps in economic policies which may serve as landmarks for action.CrossRef
3.
Zurück zum Zitat • IDF. IDF Diabetes Atlas, 8th edition. Brussels, Belgium: International Diabetes Federation; 2017. The IDF Diabetes Atlas provides a gross estimate of total health expenditure worldwide. It stands as a useful reference point for global estimates since the data is pooled from the numerous participating countries in the federation. • IDF. IDF Diabetes Atlas, 8th edition. Brussels, Belgium: International Diabetes Federation; 2017. The IDF Diabetes Atlas provides a gross estimate of total health expenditure worldwide. It stands as a useful reference point for global estimates since the data is pooled from the numerous participating countries in the federation.
5.
Zurück zum Zitat Smith-Spangler C, Bhattacharya J, Goldhaber-Fiebert J. Diabetes, its treatment, and catastrophic medical spending in 35 developing countries. Diabetes Care. 2012;35:319–26.CrossRef Smith-Spangler C, Bhattacharya J, Goldhaber-Fiebert J. Diabetes, its treatment, and catastrophic medical spending in 35 developing countries. Diabetes Care. 2012;35:319–26.CrossRef
6.
Zurück zum Zitat Stipančić G, La Grasta Sabolić L, Požgaj Šepec M, Radica A, Skrabić V, Severinski S, et al. Regional differences in incidence and clinical presentation of type 1 diabetes in children aged under 15 years in Croatia. Croat Med J. 2012;53:141–8.CrossRef Stipančić G, La Grasta Sabolić L, Požgaj Šepec M, Radica A, Skrabić V, Severinski S, et al. Regional differences in incidence and clinical presentation of type 1 diabetes in children aged under 15 years in Croatia. Croat Med J. 2012;53:141–8.CrossRef
7.
Zurück zum Zitat Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet Lond Engl. 2009;373:2027–33.CrossRef Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet Lond Engl. 2009;373:2027–33.CrossRef
8.
Zurück zum Zitat Bahendeka SK. Diabetes in sub-Saharan Africa: let us not forget type 1. Lancet Diabetes Endocrinol. 2017;5:575–7.CrossRef Bahendeka SK. Diabetes in sub-Saharan Africa: let us not forget type 1. Lancet Diabetes Endocrinol. 2017;5:575–7.CrossRef
9.
Zurück zum Zitat IDF. IDF Diabetes Atlas, 1st edition [Internet]. Brussels, Belgium: International Diabetes Federation; 2000 [cited 2015 Jan 6]. Available from: www.idf.org/diabetesatlas. Accessed 6 Sept 2018. IDF. IDF Diabetes Atlas, 1st edition [Internet]. Brussels, Belgium: International Diabetes Federation; 2000 [cited 2015 Jan 6]. Available from: www.​idf.​org/​diabetesatlas. Accessed 6 Sept 2018.
12.
Zurück zum Zitat Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20:546–51.CrossRef Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20:546–51.CrossRef
13.
Zurück zum Zitat Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60:429–62.CrossRef Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60:429–62.CrossRef
14.
Zurück zum Zitat Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.CrossRef Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.CrossRef
15.
Zurück zum Zitat Byford S, Torgerson DJ, Raftery J. Cost of illness studies. BMJ. 2000;320:1335.CrossRef Byford S, Torgerson DJ, Raftery J. Cost of illness studies. BMJ. 2000;320:1335.CrossRef
16.
Zurück zum Zitat WHO. Global status report on noncommunicable diseases, vol. 2010. Geneva: World Health Organization; 2010. WHO. Global status report on noncommunicable diseases, vol. 2010. Geneva: World Health Organization; 2010.
17.
Zurück zum Zitat WHO. Global status report on noncommunicable diseases, vol. 2014. Geneva: World Health Organisation; 2014. WHO. Global status report on noncommunicable diseases, vol. 2014. Geneva: World Health Organisation; 2014.
18.
Zurück zum Zitat Kengne AP, June-Rose McHiza Z, Amoah AGB, Mbanya J-C. Cardiovascular diseases and diabetes as economic and developmental challenges in Africa. Prog Cardiovasc Dis. 2013;56:302–13.CrossRef Kengne AP, June-Rose McHiza Z, Amoah AGB, Mbanya J-C. Cardiovascular diseases and diabetes as economic and developmental challenges in Africa. Prog Cardiovasc Dis. 2013;56:302–13.CrossRef
20.
Zurück zum Zitat Boutayeb W, Lamlili MEN, Boutayeb A, Boutayeb S. Estimation of direct and indirect cost of diabetes in Morocco. J Biomed Sci Eng. 2013;6:732–8.CrossRef Boutayeb W, Lamlili MEN, Boutayeb A, Boutayeb S. Estimation of direct and indirect cost of diabetes in Morocco. J Biomed Sci Eng. 2013;6:732–8.CrossRef
21.
Zurück zum Zitat Bermudez-Tamayo C, Besançon S, Johri M, Assa S, Brown JB, Ramaiya K. Direct and indirect costs of diabetes mellitus in Mali: a case-control study. PLoS One. 2017;12:e0176128.CrossRef Bermudez-Tamayo C, Besançon S, Johri M, Assa S, Brown JB, Ramaiya K. Direct and indirect costs of diabetes mellitus in Mali: a case-control study. PLoS One. 2017;12:e0176128.CrossRef
22.
Zurück zum Zitat •• Kirigia JM, Sambo HB, Sambo LG, Barry SP. Economic burden of diabetes mellitus in the WHO African region. BMC Int Health Hum Rights. 2009;9(6) This article presents a direct view of the cost of diabetes on more than half of the countries in Africa. It is therefore a cardinal picture as to the economic burden of diabetes in the African continent. It further shows the estimated cost of illness (diabetes) per region (country)/year. •• Kirigia JM, Sambo HB, Sambo LG, Barry SP. Economic burden of diabetes mellitus in the WHO African region. BMC Int Health Hum Rights. 2009;9(6) This article presents a direct view of the cost of diabetes on more than half of the countries in Africa. It is therefore a cardinal picture as to the economic burden of diabetes in the African continent. It further shows the estimated cost of illness (diabetes) per region (country)/year.
23.
Zurück zum Zitat Suleiman IA, Fadeke OF, Okubanjo OO. Pharmacoeconomic evaluation of anti-diabetic therapy in a Nigerian tertiary health institution. Annals of African Medicine. 2006;5:132–137. Suleiman IA, Fadeke OF, Okubanjo OO. Pharmacoeconomic evaluation of anti-diabetic therapy in a Nigerian tertiary health institution. Annals of African Medicine. 2006;5:132–137.
24.
Zurück zum Zitat Alouki K, Delisle H, Besançon S, Baldé N, Sidibé-Traoré A, Drabo J, et al. Simple calculator to estimate the medical cost of diabetes in sub-Saharan Africa. World J Diabetes. 2015;6:1312–22.CrossRef Alouki K, Delisle H, Besançon S, Baldé N, Sidibé-Traoré A, Drabo J, et al. Simple calculator to estimate the medical cost of diabetes in sub-Saharan Africa. World J Diabetes. 2015;6:1312–22.CrossRef
25.
Zurück zum Zitat Ogle GD, Kim H, Middlehurst AC, Silink M, Jenkins AJ. Financial costs for families of children with type 1 diabetes in lower-income countries. Diabet Med. 2015;33:820–6.CrossRef Ogle GD, Kim H, Middlehurst AC, Silink M, Jenkins AJ. Financial costs for families of children with type 1 diabetes in lower-income countries. Diabet Med. 2015;33:820–6.CrossRef
26.
Zurück zum Zitat Suleiman IA, Festus JA. Cost of illness among diabetes mellitus patients in Niger Delta, Nigeria. J Pharm Health Serv Res. 2015;6:53–60. Suleiman IA, Festus JA. Cost of illness among diabetes mellitus patients in Niger Delta, Nigeria. J Pharm Health Serv Res. 2015;6:53–60.
27.
Zurück zum Zitat Ngassam E, Nguewa J-L, Ongnessek S, Foutko A, Mendane F, Balla V, et al. Cout de la prise en charge du diabète de type 2 a l’hopital central de yaounde. Diabetes Metab. 2012;38:A105.CrossRef Ngassam E, Nguewa J-L, Ongnessek S, Foutko A, Mendane F, Balla V, et al. Cout de la prise en charge du diabète de type 2 a l’hopital central de yaounde. Diabetes Metab. 2012;38:A105.CrossRef
28.
Zurück zum Zitat Abdulganiyu G, Tayo F. What is the cost of illness of type II diabetes mellitus in a developing economy? Int J Pharm Pharm Sci. 2014;6:929–31. Abdulganiyu G, Tayo F. What is the cost of illness of type II diabetes mellitus in a developing economy? Int J Pharm Pharm Sci. 2014;6:929–31.
29.
Zurück zum Zitat Quaye EA, Amporful EO, Akweongo P, Aikins MK. Analysis of the financial cost of diabetes mellitus in four cocoa clinics of Ghana. Value Health Reg Issues. 2015;7:49–53.CrossRef Quaye EA, Amporful EO, Akweongo P, Aikins MK. Analysis of the financial cost of diabetes mellitus in four cocoa clinics of Ghana. Value Health Reg Issues. 2015;7:49–53.CrossRef
30.
Zurück zum Zitat Elrayah-Eliadarous H, Yassin K, Eltom M, Abdelrahman S, Wahlström R, Östenson C-G. Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes. 2010;118:220–5.CrossRef Elrayah-Eliadarous H, Yassin K, Eltom M, Abdelrahman S, Wahlström R, Östenson C-G. Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes. 2010;118:220–5.CrossRef
31.
Zurück zum Zitat Elrayah H, Eltom M, Bedri A, Belal A, Rosling H, Ostenson C-G. Economic burden on families of childhood type 1 diabetes in urban Sudan. Diabetes Res Clin Pract. 2005;70:159–65.CrossRef Elrayah H, Eltom M, Bedri A, Belal A, Rosling H, Ostenson C-G. Economic burden on families of childhood type 1 diabetes in urban Sudan. Diabetes Res Clin Pract. 2005;70:159–65.CrossRef
32.
Zurück zum Zitat Chale S, Swai A, Mujinja P, McLarty D. Must diabetes be a fatal disease in Africa? Study of costs of treatment. BMJ. 1992;304:1215–8.CrossRef Chale S, Swai A, Mujinja P, McLarty D. Must diabetes be a fatal disease in Africa? Study of costs of treatment. BMJ. 1992;304:1215–8.CrossRef
33.
Zurück zum Zitat Ipingbemi AE, Erhun WO. Cost implications of treatment of diabetes mellitus in a secondary healthcare facility in Ibadan. Afr J Med Med Sci. 2015;44:79–87.PubMed Ipingbemi AE, Erhun WO. Cost implications of treatment of diabetes mellitus in a secondary healthcare facility in Ibadan. Afr J Med Med Sci. 2015;44:79–87.PubMed
34.
Zurück zum Zitat Okoronkwo IL, Ekpemiro JN, Okwor EU, Okpala PU, Adeyemo FO. Economic burden and catastrophic cost among people living with type 2 diabetes mellitus attending a tertiary health institution in south-east zone, Nigeria. BMC Res Notes. 2015;8. Okoronkwo IL, Ekpemiro JN, Okwor EU, Okpala PU, Adeyemo FO. Economic burden and catastrophic cost among people living with type 2 diabetes mellitus attending a tertiary health institution in south-east zone, Nigeria. BMC Res Notes. 2015;8.
35.
Zurück zum Zitat Danmusa UM, Terhile I, Nasir IA, Ahmad AA, Muhammad HY. Prevalence and healthcare costs associated with the management of diabetic foot ulcer in patients attending Ahmadu Bello University Teaching Hospital, Nigeria. Int J Health Sci. 2016;10:219–28. Danmusa UM, Terhile I, Nasir IA, Ahmad AA, Muhammad HY. Prevalence and healthcare costs associated with the management of diabetic foot ulcer in patients attending Ahmadu Bello University Teaching Hospital, Nigeria. Int J Health Sci. 2016;10:219–28.
36.
Zurück zum Zitat Ogbera AO, Fasanmade O, Ohwovoriole AE, Adediran O. An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. Int J Low Extrem Wounds. 2006;5:244–9.CrossRef Ogbera AO, Fasanmade O, Ohwovoriole AE, Adediran O. An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. Int J Low Extrem Wounds. 2006;5:244–9.CrossRef
37.
Zurück zum Zitat Cavanagh P, Attinger C, Abbas Z, Bal A, Rojas N, Xu Z-R. Cost of treating diabetic foot ulcers in five different countries. Diabetes Metab Res Rev. 2012;28(Suppl 1):107–11.CrossRef Cavanagh P, Attinger C, Abbas Z, Bal A, Rojas N, Xu Z-R. Cost of treating diabetic foot ulcers in five different countries. Diabetes Metab Res Rev. 2012;28(Suppl 1):107–11.CrossRef
38.
Zurück zum Zitat Mutyambizi C, Pavlova M, Chola L, Hongoro C, Groot W. Cost of diabetes mellitus in Africa: a systematic review of existing literature. Glob Health. 2018;14:3.CrossRef Mutyambizi C, Pavlova M, Chola L, Hongoro C, Groot W. Cost of diabetes mellitus in Africa: a systematic review of existing literature. Glob Health. 2018;14:3.CrossRef
39.
Zurück zum Zitat Mbanya J-C, Mbanya D. Diabetes cost in sub-Saharan Africa. J Cardiovasc Risk. 2003;10:191–3.PubMed Mbanya J-C, Mbanya D. Diabetes cost in sub-Saharan Africa. J Cardiovasc Risk. 2003;10:191–3.PubMed
40.
Zurück zum Zitat Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. PharmacoEconomics. 2001;19:207–13.CrossRef Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. PharmacoEconomics. 2001;19:207–13.CrossRef
41.
Zurück zum Zitat Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy Amst Neth. 2006;77:51–63.CrossRef Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy Amst Neth. 2006;77:51–63.CrossRef
Metadaten
Titel
Economic Impact of Diabetes in Africa
verfasst von
Clarisse Mapa-Tassou
Jean-Claude Katte
Camille Mba Maadjhou
Jean Claude Mbanya
Publikationsdatum
01.02.2019
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 2/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1124-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.